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“Like the entomologist hunting 
for brightly colored butterflies,  
my attention was drawn 
  to the flower garden of the grey matter,  
which contained cells 
 with delicate and elegant forms,  
the mysterious butterflies of the soul,  
 the bearing of whose wings may some day 
 clarify the secret of mental life.”  
 
- Santiago Ramón y Cajal, Recollections of My Life 
 
 
 
  
ABSTRACT 
 
 
A mood-congruent processing bias toward negative emotional information is a 
hallmark characteristic of the pathophysiology of major depressive disorder (MDD). 
Previous neuropsychological studies have provided evidence of this phenomenon in 
memory and attention paradigms. In addition, functional neuroimaging studies 
consistently report increased neural responses to negative emotional stimuli, including 
words and faces.  
The amygdala plays an essential role in the determining the salience of a 
stimulus and is particularly tuned to the evaluation of facial expressions.  Two 
pathways to the amygdala have been proposed: one involving higher-order cortical 
regions that permits explicit stimulus perception and one involving subcortical 
structures that allows rapid detection of non-conscious or implicit stimuli of emotional 
significance.  
Several studies have explored the nature of explicit emotional face processing 
in MDD. However, few have focused on how the brain responds to non-conscious or 
implicit emotional information. Altered processing of emotional information, below the 
level of explicit conscious awareness, may contribute to the establishment and 
maintenance of illness-associated symptoms involving dysfunctional conscious 
perceptions and social interactions. Providing further evidence, recent research suggests 
that the mechanisms underlying antidepressant treatment may involve a reversal of the 
negative emotional processing bias associated with MDD.  
The purpose of this thesis was to investigate the functional anatomical neural 
network of structures involved in mood-congruent processing biases toward non-
conscious emotional information in MDD and to evaluate differences in this network 
associated with antidepressant treatment. 
In Study I, a novel backward masking task was developed to examine 
differences in the hemodynamic response of the amygdala to sad (SN), happy (HN) and 
neutral (NN) faces presented below the level of explicit conscious awareness using 
functional magnetic resonance imaging (fMRI). Participants included individuals with 
current major depressive disorder (dMDD), MDD in full remission (rMDD) and 
healthy controls (HC). A subset of dMDD participants completed the fMRI task before 
and after eight weeks of antidepressant treatment with sertraline hydrochloride. An 
amygdala region-of-interest analysis revealed a greater hemodynamic response in the 
amygdala to masked-sad vs. masked-happy faces (SN-HN) in dMDD vs. HC. In 
contrast, HC participants showed a greater response to masked-happy faces. rMDD 
participants also showed a negative processing bias toward masked-sad faces similar to 
the dMDD group. In dMDD, the negative processing bias reversed and a positive 
processing bias emerged following antidepressant treatment. 
In Studies II and III, a regional analysis of the cortical and subcortical networks 
involved with the amygdala in processing emotional information was used to evaluate 
differences between the dMDD and HC participants and dMDD participants before and 
after antidepressant treatment from Study I. In Study II, dMDD participants showed a 
  
greater hemodynamic response to SN-HN in the hippocampus and anterior 
inferotemporal cortex. As well, participants showed a greater response to SN-NN or 
HN-NN in areas of the medial and orbital prefrontal cortex and superior temporal 
gyrus. In Study III, dMDD participants showed a greater response to SN-HN in the pre- 
vs. post-treatment condition in the pregenual anterior cingulate cortex, superior 
temporal gyrus and anterior inferotemporal gyrus. Additional regions of the sensory 
and visceromotor networks also showed an increased hemodynamic response to SN-
NN before versus after treatment. The regions associated with these differential 
responses are known to participate with the amygdala in evaluating and responding to 
the salience of emotional stimuli.  
Taken together, these studies provide insight into the underlying neurocircuitry 
associated with the processing of non-conscious emotional information. Furthermore, 
they reveal networks that are influenced by antidepressant treatment to alter brain 
function and establish a reversal of the negative processing bias and development of a 
normative positive processing bias in major depressive disorder. 
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1 INTRODUCTION 
 
According to the World Health Organization, major depressive disorder (MDD) 
is the leading cause of years lived with a disability across all age groups. By the year 
2020, depression is expected to become the second leading cause of disability-adjusted 
life years, or years of life lost due to premature mortality, second only to ischemic heart 
attack. Over 120 million people are estimated to suffer from depression worldwide. 
MDD is also associated with an increased risk of suicide and approximately 15-20% of 
depressed individuals end their lives by committing suicide, a leading cause of death in 
young adults 1.  
 
Major depressive disorder is characterized by persistent depressed mood and/or 
loss of interest and pleasure, in addition to feelings of hopelessness, worthlessness, or 
guilt, diminished concentration or indecisiveness, fatigue, recurrent thoughts of death 
or suicide, and difficulties with psychomotor activity, weight loss or gain, sleep and 
appetite 2. The clinical symptomatology of MDD involves brain systems responsible 
for the regulation of mood, attention, anxiety, reward processing, motivation, social 
function, and autonomic function (e.g. sleep, energy, weight, libido) 2. 
 
Despite the enormous burden on an individual’s life and society, the 
pathogenesis of major depressive disorder has been poorly characterized until recent 
years, due to a lack of gross brain abnormalities or clear animal models associated with 
the recurrent MDD 3. Advances in neuroimaging technologies, such as functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) have 
provided methods of non-invasive assessment of the functional, structural and 
neurochemical abnormalities underlying the pathophysiology of mood disorders 3. In 
particular, the elucidation of the functional neuroanatomical correlates of emotion 
regulation has been of importance in advancing psychiatric research. Knowledge 
concerning the neurophysiological correlates of emotion regulation will aid in the 
understanding of how these processes are altered and may be reversed with proper 
treatment. The significance of the proposed study lies in its contribution to the 
understanding of the specific neuroanatomical correlates, neurophysiological 
processes, and neural pathways involved in emotional processing and the potential to 
establish effective treatment mechanisms in major depressive disorder. 
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1.1 FUNCTIONAL MAGNETIC RESONANCE IMAGING 
 
Methods for functional brain imaging have been developed that use magnetic 
resonance imaging (MRI) to observe activity-related, hemodynamic response changes 
with spatial and temporal resolution. Functional MRI (fMRI) is predicated on the 
magnetic properties of the hydrogen atom. When a subject is placed in the scanner, a 
radio frequency pulse is applied which affects proton alignment in the hydrogen atom. 
Upon completion of the pulse sequence, the protons attempt to realign, thereby emitting 
energy that can be interpreted as signal strength. The most commonly used method of 
functional imaging examines changes in blood oxygenation, such that neural activity is 
measured indirectly by the blood oxygen level-dependent contrast (BOLD) 4,5. Because 
of the different magnetic properties of oxy- and deoxyhemoglobin, increased levels of 
blood oxygenation are associated with increased signal for T2*-weighted gradient echo 
imaging and echo planar imaging (EPI).  Increased neural activity is associated with 
this increased signal 4.  Because the change in signal is due to properties inherent in the 
blood, MRI is non-invasive and eliminates the need for injection of contrast agents or 
radiation exposure. Therefore, this method provides an advantage in the evaluation of 
neural activity over other brain imaging techniques, such as positron emission 
tomography (PET). 
 
 A limitation of BOLD susceptibility-contrast based fMRI is that the magnetic 
resonance signal obtained using T2*-weighted images is also sensitive to other sources 
of magnetic susceptibility. A problematic artifact in these images is the artifact 
associated with air in the bony sinuses of the skull (e.g. sphenoid sinus), which 
attenuates the MR signal in orbitofrontal and anterior temporal cortex 6. The extent of 
MR signal dropout from such susceptibility artifacts worsens as the magnetic field 
strength of the MRI scanner increases. By shortening the echo time (TE) and 
employing smaller voxel sizes in the present study, signal susceptibility artifacts were 
sufficiently reduced in the orbitofrontal cortex to allow for sensitive measures of the 
BOLD signal in this region. 
   
1.2 NEURAL CIRCUITRY INVOLVED IN DEPRESSION 
 
The convergence of neuroimaging, neuropathological and lesion studies has 
resulted in the identification of networks within the brain involved in the regulation of 
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emotional behavior in mood disorders 7. These regions include the limbic-cortical-
striatal-pallidal-thalamic circuit which is comprised of multiple connections between 
areas of the orbital and medial prefrontal cortex (PFC), hippocampus, amygdala, and 
related structures in the striatum and thalamus 8. These circuits were initially thought 
to be involved in depression based on the increased risk for developing MDE in 
persons with basal ganglia disease or lesions of the striatum and orbital cortex 9. 
Dysfunction in these circuits has been proposed to result in the pathological 
emotional symptoms of a major depressive episode (MDE) 10.  
 
Two additional extended cortical circuits within the brain have been identified 
based largely on neuroanatomical studies of monkeys 11. The first, referred to as the 
“orbital prefrontal network”, involves sensory association areas of the inferior 
temporal cortex, insula and frontal operculum. This circuit is responsible for sensory 
integration, critical assessment of objects and the anticipation of reward 11. The 
second extended cortical circuit is the “medial prefrontal network” or “visceromotor” 
network. This network involves the amygdala and interconnections with the medial 
prefrontal cortex, caudolateral orbital cortex, anterior and medial temporal cortex and 
posterior cingulate cortex, as well as subcortical structures such as the striatum, 
thalamus, hypothalamus and brainstem 11,12. The visceromotor network, in contrast to 
the medial prefrontal system with its sensory-related functions, is involved in the 
modulation of visceral responses to emotional stimuli and is implicated the 
pathophysiology of mood disorders 12. Both networks have shown abnormalities in 
depressed individuals during fMRI studies of reward and emotion, however the 
visceromotor network has been more specifically implicated in mood disorders 13,14.  
 
The subgenual and pregenual regions of the anterior cingulate cortex (ACC) 
have been implicated in the neurobiology of MDD and bipolar disorder (BD) 15,16.  
Both areas are known to be associated with autonomic, neuroendocrine, and 
monoamine neurotransmitter modulation in response to stressful and emotionally 
provocative stimuli (16 for a review). In PET imaging, after correcting for the effects 
of a left-lateralized reduction in gray matter volume, cerebral blood flow and 
metabolism are abnormally increased in the subgenual ACC in depressed patients 
versus controls 15,17,18. Providing further support for this finding, cerebral blood flow 
(CBF) increases in the subgenual ACC in response to induced sadness in healthy 
individuals 19-21 and following effective antidepressant treatment, glucose metabolism 
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decreases to normative levels in MDD 17,21-23. Pregenual ACC cerebral blood flow 
and metabolism findings are more variable than the subgenual ACC, however most 
imaging studies report increases during major depressive episodes, consistent with 
elevated CBF during emotional conditions found in healthy and anxiety-disordered 
individuals 16, and normalized metabolism following successful treatment 15,24.  
Electrical stimulation of this region elicits fear, panic, and a sense of foreboding in 
humans and vocalization in experimental animals [25 for a review]. 
 
In addition to the ACC, several other prefrontal cortical regions exhibit 
neurophysiological abnormalities in major depressive disorder, including the 
dorsomedial and dorsolateral PFC, ventrolateral PFC, and posterolateral orbital 
cortex. In the dorsomedial and dorsolateral PFC, resting CBF and glucose metabolism 
are reduced in depressed individuals compared to controls 26-28, while CBF increases 
in these areas during performance of tasks that elicit emotional responses or 
evaluations in healthy controls 29-31. The dorsomedial PFC may also play a role in 
attenuation of emotional responses, as increases in CBF are inversely correlated with 
decreases in heart rate and anxiety ratings during anticipation of a shock 32. In 
depressed individuals, CBF and glucose metabolism in the dorsomedial and 
dorsolateral PFC have been shown to normalize with effective antidepressant 
treatment in some studies 23,26,27,33, but not all 34,35. Lesions of this area in rats result in 
an increased heart rate response to fear-conditioned stimuli, and stimulation of this 
area inhibits heart responses and defensive behaviors evoked by stimulation of the 
amygdala 36.   
 
In the ventrolateral and posterolateral orbital cortex, CBF and metabolism are 
reportedly increased in unmedicated, unipolar depressed individuals 30,37,38, and 
decrease with successful antidepressant treatment 21,39,40. In healthy individuals, CBF 
in the posterolateral orbital cortex increases during induced sadness or anxiety.  
Electrophysiological and lesion studies suggest a role for the posterior orbital cortex 
in the modulation of defensive, autonomic, and behavioral response patterns to 
reward and perseveration on inappropriate strategies 41,42. Furthermore, the role of the 
posterior orbital cortex may be partially influenced by interactions with the amygdala 
and other limbic structures due to direct projections to each other and overlapping 
projections to the striatum, hypothalamus, and periaqueductal gray (PAG) 43,44. 
Compatible with this finding, glucose metabolism in the orbital cortex and amygdala 
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are inversely correlated in depressed individuals 22. As well, similar to the subgenual 
ACC, gray matter and glial cells are reduced in MDD in the posterolateral orbital 
cortex 28,45. If this abnormality is associated with altered synaptic connections 
between these areas above, then orbital dysfunction may contribute to exaggerated 
emotional responses to stressors and ruminative ideation 24.  During a major 
depressive episode (MDE), activation of the posterolateral orbital cortex may be part 
of an effort to attenuate emotional expression, break negative thought patterns, and 
inhibit defensive behaviors and visceral responses to stressors 15,16. If the 
posterolateral orbital cortex is activated in MDD in an attempt to correct abnormal 
responses and modulate emotional expression, abnormalities may result in the 
inability to interrupt perseverative negative thoughts and anxious responses to 
otherwise non-threatening stimuli 46. 
 
While the prefrontal cortex has multiple regions implicated in the abnormal 
neurophysiology associated with MDD, several other subcortical structures also play 
a very important role, such as the amygdala, striatum, and thalamus.  In humans, 
electrical stimulation of the amygdala can produce anxiety, fear, dysphoria, 
recollection of emotionally provocative events, and an increase in cortisol secretion 
[47 for a review].  In MDD, resting cerebral blood flow and glucose metabolism are 
abnormally elevated in the amygdala and medial thalamus 30,37,48-50.  The magnitude 
of this abnormality when corrected for spatial resolution effects is an actual increase 
in CBF and metabolism of about 50%-70% 37,51.  Antidepressant treatment induces 
and maintains remission of MDD and is associated with the normalization of 
amygdala metabolism 39.   
 
1.3 RECIPROCAL INTERACTIONS BETWEEN AMYGDALA AND 
PREFRONTAL CORTEX 
 
The amygdala is an almond-shaped structure located within the medial 
temporal lobe of the brain. It is composed of a group of nuclei with extensive 
interconnections throughout cortical and subcortical regions. The amygdala contains 
cells that are selectively tuned toward stimulus characteristics that permit the rapid 
detection of salient information 52,53. The amygdala has also been shown to influence 
the sensory cortices such that they are differentially sensitive to salient signals 54,55. 
The amygdala has been extensively studied as a region involved in the 
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pathophysiology of fear and anxiety processes in the brain, often using the approach 
of classical fear conditioning. This paradigm has shown that fear is processed through 
a series of circuits that detect and respond to danger 56. The pathway underlying fear 
conditioning involves the communication of information to the amygdala through the 
thalamus and cortex to networks in the brain that influence behavioral, autonomic, 
and endocrine responses 57,58. Functional neuroimaging studies have implicated the 
role of the amygdala in the processing of fear and evaluation of emotional 
significance to stimuli 59,60. The amygdala has been shown to play a role in fear 
conditioning 61,62, recognizing facial expressions 63-65, and abnormal amygdala 
response in the context of depression and anxiety 66,67.   
 
 Two pathways have been proposed to explain how sensory information 
reaches the amygdala. More specifically, these two pathways involve thalamo-
cortico-amygdala (cortical) and thalamo-amygdala (subcortical) projections. These 
projections pass through the thalamus and terminate in the lateral amygdala which 
generates responses to visual and auditory inputs. Information then continues from 
the lateral amygdala to the central nucleus of the amygdala, by way of the basal and 
accessory basal nuclei, which control the expression of the emotional response 58.  
The thalamo-amygdala pathway is thought to be rapid response system for visual and 
auditory stimuli and involved in mediating fear responses to stimuli presented below 
the level of conscious awareness 60. In contrast, the thalamo-cortico-amygdala 
pathway is involved in processing more complex sensory information requiring 
cortical inputs necessary for information processing 58,68,69.  Functional neuroimaging 
studies have shown increases in amygdala activity during the presentation of 
subconscious stimuli, in which the most robust relationships are found between the 
amygdala and subcortical structures, providing further evidence for the role of a 
subcortical pathway in the human brain 70,71. 
 
 The amygdala receives multiple inputs from sensory processing cortical areas, 
including reciprocal connections with the PFC.  When the amygdala is activated by a 
sensory stimulus by receiving input from the thalamus or cortex, it can also regulate 
cortical areas with projections to the amygdala, thereby controlling the type of input it 
receives 56. The medial PFC provides important feedback to the amygdala and 
hippocampus, which may represent a ‘top down’ processing of their response, 
enabling the reduction of a fear response once an imminent danger is no longer 
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present or the meaning of a threatening stimulus changes context 72 and extinction of 
conditioned responses to stimuli 73,74. In both animal data and human brain imaging, 
the amygdala has been implicated in fear conditioning and the PFC with a role in the 
process of extinction of fear responses 72. In rats, it has been demonstrated that 
damage to the medial PFC results in fear that is difficult to extinguish 75. This 
suggests that alterations in medial prefrontal cortical regions may predispose certain 
people in some circumstances, such as stressful situations, to learn fear responses that 
persist under normal circumstances.  Garcia et al. 76 showed that prefrontal neurons 
reduce their spontaneous firing activity in the presence of a conditioned stimulus as a 
function of the degree of fear.  As well, the reduction was related to amygdala 
activity. They provide evidence that in the presence of threatening stimuli, the 
amygdala modulates both fear expression and prefrontal neuronal activity. This 
suggests that the abnormal amygdala-induced modulation of activity in the PFC may 
be involved in the pathophysiology of disorders with anxiety components 76. In 
preliminary PET data in humans with anxiety disorders, dysfunction of medial 
prefrontal cortical structures (i.e. the ACC and infralimbic cortex) is associated with 
the abnormal expression of anxiety and fear 67. Given the reciprocal connections the 
amygdala and prefrontal cortical structures, the amygdala is in a position to activate 
the PFC and modulate interactions between the PFC and medial thalamus and 
influence both emotional and stress responses 22. Pathological changes in the top-
down control of this network of regions may be responsible for the manifestation of 
the symptoms of major depressive disorder. Impairment could result in an 
exaggerated response to threatening or negative stimuli and a reduction in the 
response to rewarding or positive stimuli 12,77,78. 
 
1.4 MOOD-CONGRUENT EMOTIONAL PROCESSING BIASES 
 
Studies of emotional processing biases often center on the wealth of 
information contained in human faces. In his pioneering work on emotion, Charles 
Darwin hypothesized that emotions were genetically determined and that basic 
emotions were universal in all mammals 79. More recently, Paul Ekman’s research on 
facial expressions as representatives of emotion has resulted in six universal 
expressions: anger, disgust, fear, happiness, sadness and surprise 80. This work 
continues to influence our understanding of emotion and provides the foundation for 
the vast amount of research performed to evaluate emotion-specific neurophysiological 
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responses 81 and gain further insight into neuropsychiatric disorders associated with 
abnormalities in emotional processing. 
 
A mood-congruent processing bias toward negatively-valenced emotional 
stimuli is a consistent feature in the pathophysiology of major depressive disorder 
(MDD). This bias is described as a stimulus processing bias toward negative emotional 
information as compared to neutral or positive information. This bias is evident in 
behavioral measures that evaluate memory and attention 82-85. In studies of memory, 
depressed patients show increased memory recall for negatively toned information in 
comparison with positively toned information 82,85. In studies of attention, both 
medicated and unmedicated depressed subjects show faster reaction times during the 
presentation of sad words as compared to happy words during the affective go/no-go 
task that evaluates shifts in attention biases. 84,86. As well, depressed patients have been 
shown to attend to sad facial expressions compared to neutral expressions using the 
face dot-probe task 83. Taken together, these behavioral studies show a consistent 
preference toward negatively-valenced information in depression. 
 
Consistent with behavioral findings, mood-congruent processing biases are also 
evident in neurophysiological indices 3,87-92. In normal controls, several functional 
imaging studies have shown greater amygdala activity in response to overt negatively 
valenced fearful or sad faces in comparison with neutral or happy faces 64,65,93-95. In 
addition, healthy controls have been shown to exhibit a linear increase in activity in 
the fusiform cortex and ventral striatum with increases in the intensity of happy 
expressions 96. In the same study, depressed patients showed a similar pattern of 
response as the intensity of sad expressions increased and this finding was further 
extended to include the hippocampus and amygdala. In major depressive disorder, 
normal increases of the hemodynamic response are attenuated in the left amygdala 
during exposure to fearful facial expressions, whereas the response to sad faces is 
exaggerated in depressed individuals relative to controls 22. Attenuated responses of 
the left amygdala during presentation of fearful faces relative to neutral and sad faces 
have been found in both depressed children 97 and adults 98. This response 
(attenuation of tissue that is already abnormally activated) is consistent with findings 
of abnormally elevated CBF and glucose metabolism in the amygdala of depressed 
individuals at rest 24,37. Finally, the hemodynamic response to explicitly presented sad 
faces is exaggerated in the amygdala in depressed individuals compared to healthy 
   9 
controls 96, and this abnormality normalizes following antidepressant drug treatment 
(ADT) 99. Given the differences in hemodynamic response of the amygdala at rest and 
during the presentation of emotional facial expressions between depressed individuals 
and controls, it is plausible that amygdala dysfunction may alter the interpretation of 
social or emotional stimuli in mood disorders 24.   
 
Drevets et al. 98 investigated amygdala and PFC functioning toward sad faces in 
individuals with MDD using PET.  Increases in CBF in the left amygdala and 
prefrontal cortical regions were found in the depressed relative to control individuals.  
Increased amygdala activation in the depressed individuals was explained by a lack of 
habituation to the sad faces.  In the control individuals, amygdala activation decreased 
with multiple presentations of the sad faces, suggesting a habituation response to 
emotional stimuli that are familiar 64,97.  The table below reviews a number of regions 
exhibiting abnormal hemodynamic responses in the orbitomedial PFC and areas with 
connections to this region associated with differential amygdala responses to 
emotionally valenced stimuli between depressed and healthy control individuals. 
 
Differential Hemodynamic Responses To Facial Emotion:  Depressed vs. Healthy 
Controls. 
 
    In Healthy        In Depression to       Sad, Fear Ventromedial PFC (24/32/10m) 
                    Sad, Fear Pregenual ACC (24) 
                    Fear Left Ventrolateral Amygdala, 
    Hypothalamus, 
    Periaqueductal Gray Nucleus 
    In Healthy      In Depression to        Sad, Fear Dorsal Temporal Pole 
                    Sad, Fear Parahippocampal Gyrus 
                    Sad Posterior Cingulate,                  
    Anteroventral Striatum, 
    Dorsomedial PFC (9/32) 
                    Fear Infralimbic C (25), 
    Dorsal Area 32 
 
1.5 BACKWARD MASKING OF EMOTIONALLY VALENCED STIMULI 
 
Conscious feelings do not appear to be required to produce emotional responses 
that, like cognitive processes, involve subconscious processing mechanisms 60,100.  In 
addition to the study of the conscious processing of emotional stimuli using facial 
emotion described above, there has been an increasing amount of literature concerning 
the non-conscious processing of emotional stimuli using a technique known as 
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backward masking.   Arne Öhman and his colleagues were the first researchers to 
demonstrate differences in automatic learning via a classical conditioning paradigm 
combined with backward masking in healthy controls and individuals with anxiety 
disorders 101.  In the technique of backward masking, two stimuli are presented with the 
second stimulus following the first so quickly that the neural processing of the original 
stimulus is interrupted by the presentation of the second and is therefore not detected by 
the individual.  Behavioral studies suggest that stimulus-stimulus associations can be 
formed implicitly (i.e. without the subject’s awareness) when the stimuli involved are 
biologically salient (e.g., snakes, spiders, or angry faces) 102,103.   
 
Early strategies for the backward masking procedure involved conditioning the 
presentation of a facial expression to predict an aversive shock.  This has been done in 
two ways described in Whalen et al. 101:  The first method involves presenting the facial 
stimuli overtly (unmasked) during conditioning and then recording participant 
responses (i.e. skin conductance responses (SCRs)) during masked presentations.  This 
method seeks to determine if responses to previously learned associations can occur 
when later presented below conscious awareness.  In a second method, backward 
masking during conditioning is used to assess whether subsequent presentations of 
unmasked faces produce greater responses to the face that predicted the aversive event 
in the masked presentations.  This method seeks to determine if individuals can learn 
the conditioned association when they are initially presented below conscious 
awareness, as indicated by a subject’s inability to describe having seen the masked 
stimulus.   Using these methods, studies have demonstrated that greater SCRs can be 
produced to backwardly masked stimuli following previously learned overtly presented 
associations between the stimulus and aversive event and also greater SCRs to overtly 
presented stimuli that were previously conditioned using masked stimuli presented 
below the level of conscious awareness 100,104-110.   
 
Presentations of masked emotional stimuli have been fairly reliable in obtaining 
differential behavioral (i.e. SCRs) and neurophysiological responses in healthy and 
anxiety-disordered individuals.  Backward masking is of important relevance to anxiety 
disorders and disorders with anxiety components given that this technique is designed 
to evaluate the automaticity of emotional processing in the brain.  These disorders are 
associated with an automatic information processing bias for negative information, 
such as involuntary and spontaneous obsessions, panic attacks, or ruminative negative 
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thoughts.  Given the high comorbidity of anxiety-related symptoms with mood 
disorders and the common neural structures and pathways implicated in the 
pathophysiology of these disorders with regard to emotional processing, backward 
masking is a technique that may prove to be useful in determining the underlying 
dysfunction of processing emotional stimuli.  This technique allows for the assessment 
of automatic processing of emotional stimuli as opposed to a controlled level of 
information processing, which may play a key role in understanding the manifestation 
of dysfunctional emotional processing in mood and anxiety disorders. 
 
While the majority of what is known about backward masking has been 
established by measuring changes in SCRs to aversively conditioned stimuli, many 
studies have used this technique in fMRI studies as well, focusing on the role of the 
amygdala in the processing of emotional faces.  Based on animal studies indicating the 
thalamo-amygdala projections are involved in rapid conditioning 111, Le Doux 60 
proposed that processing emotionally valenced stimuli presented below the level of 
conscious awareness would involve the amygdala.   In fMRI studies where emotional 
faces were presented below the level of awareness using a “masked” face paradigm, the 
amygdala was activated in healthy individuals 93,94, indicating that conscious perception 
is not necessary for detection at the subcortical level.   Whalen et al. 94 studied 
amygdala responses to backwardly masked-fearful and happy facial expressions in the 
absence of explicit knowledge and reported increased bilateral amygdala activation to 
masked-fearful vs. masked-happy faces in healthy individuals.  Morris and Öhman 71 
demonstrated a significant neural response in the right amygdala to masked 
presentations of a conditioned angry face, and a significant neural response in the left 
amygdala to unmasked presentations of the same face.  Specifically in individuals with 
MDD, Sheline et al. 112 reported that hemodynamic responses in the left amygdala were 
increased in MDD subjects exposed to masked-fearful vs. masked-happy faces.   
Sheline et al. 112 further showed that this exaggerated left amygdala activity to masked-
fearful faces was attenuated in MDD individuals following sertraline treatment.  The 
magnitude of the BOLD response to masked-fearful faces did not change over the same 
time interval in healthy controls.  
 
As discussed above, the amygdala plays a pivotal role in evaluating the emotional 
salience of sensory stimuli through participation in two distinct types of distributed 
networks, one involving cortical regions that allow conscious or explicit stimulus 
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perception, and the other involving subcortical structures that allow rapid, non-
conscious assessment of stimulus features 53,60. Notably, healthy subjects show greater 
amygdala responses to happy versus sad faces when stimuli are presented below 
conscious awareness. This finding suggests the existence of a normal positive 
processing bias that is supported by subcortical networks which mediate rapid, 
automatic emotional evaluations 113,114. Thus, it is plausible that the negative processing 
bias that characterizes MDD may be mediated by this rapid, non-conscious processing 
network involving the amygdala and may also implicate the dysfunctional limbic-
cortical network involved in mood and anxiety disorders. Neurophysiological responses 
to non-conscious emotional stimuli in specific regions of the limbic-cortical network 
remain largely unknown.  
 
1.6 NEUROIMAGING ABNORMALITIES AND ANTIDEPRESSANT 
TREATMENT 
 
 The neuroimaging measures with abnormalities in MDD that show changes in 
response to effective antidepressant drugs or mood stabilizers include: resting glucose 
metabolism in the amygdala, anterior cingulate cortex, and ventral striatum, 
hemodynamic responses to emotional faces in the amygdala and ACC, gray matter 
volume of the subgenual ACC, and serotonin type 1A receptor binding in the raphe and 
mesiotemporal cortex 23,33,112,115-120. These findings implicate neurobiological systems 
shown by electrophysiological, lesion analysis, or PET/fMRI studies to play major 
roles in emotional behavior. These neuroimaging abnormalities have been replicated 
across laboratories, and are associated with histopathological correlates in post mortem 
studies of primary MDD (121 for a review). 
 
 Studies designed to evaluate the effects of antidepressant treatment on the 
neurocircuitry involved in MDD may elucidate the mechanisms underlying the outward 
expression of the benefits of pharmacotherapy. Longitudinal studies in which depressed 
subjects are imaged before and during treatment show that CBF and metabolism 
decrease in the left amygdala, orbital cortex,  ventromedial PFC, pregenual and 
subgenual ACC and anterior insula following effective antidepressant drug therapy, 
ECT, phototherapy, repeated transcranial magnetic stimulation (rTMS), and sleep 
deprivation (see 46 for a review).  The reduction in amygdala metabolism during 
treatment correlates positively with clinical improvement (decrease in depression 
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ratings) and with the reduction in plasma cortisol levels 116.  Amygdala hemodynamic 
responses to emotionally valenced stimuli are also suppressed by chronic antidepressant 
drug treatment 99,112,122.  These data are consistent with preclinical evidence suggesting 
that chronic antidepressant drug treatments directly suppress amygdala function 123-127. 
In addition, similar effects on the amygdala have been shown following acute 
antidepressant drug administration. For example, citalopram administered three hours 
prior to scanning decreases the amygdala response to fearful expressions 128 and similar 
results have been shown after seven days of administration with reboxetine and 
citalopram 129,130. 
 
 A recent hypothesis has proposed a cognitive neuropsychological model of 
antidepressant action, such that the primary therapeutic mechanism of antidepressant 
treatment is to normalize negative processing biases, thereby influencing the 
interpretation of salient personal and social information 131,132. As well, it has been 
hypothesized that the clinical effects of antidepressant treatment lag behind the 
normalization of emotional processing biases because environmental and social 
interaction is required before a change in the emotional bias can overtly affect mood 
and behavior 132. Evidence in support of this hypothesis has been shown in healthy 
individuals during the short-term administration of citalopram, which increased 
amygdala response to happy faces 133 and in depressed patients who after a single dose 
of reboxetine showed enhanced behavioral responses to positive stimuli 134. These 
findings suggest that changes in emotional processing biases commonly occur under 
antidepressant treatments that are diverse with respect to their primary pharmacological 
mechanisms of action. Furthermore, these changes in the processing of emotional 
information at an early stage may contribute to and influence the change in mood and 
improvement in symptoms associated with MDD later in the course of treatment 134.  
  
Among antidepressants, sertraline is a first line antidepressant drug for treating 
MDD given its established efficacy and more benign adverse risk and side effect 
profiles. For these reasons, sertraline was selected as the antidepressant treatment for 
the pharmacotherapy component of the thesis work.  Sertraline has been shown to be as 
effective and well-tolerated as other selective serotonin reuptake inhibitors (SSRI)s, 
which function to inhibit the uptake of serotonin from the synapse.  Sertraline has a 
relatively low tendency for altering the metabolism of other drugs relative to similar 
SSRIs because it has low potency for inhibiting the hepatic cytochrome P450 enzymes.  
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Risks or side effects associated with sertraline and other SSRIs include induction of 
hypomania, allergic reactions, gastrointestinal side effects, insomnia, agitation, anxiety, 
sedation, sexual dysfunction, and rarely, the syndrome of inappropriate secretion of 
antidiuretic hormone.  Sertraline has rarely been fatal in cases in which suicidal patients 
took an intentional medication overdose. However, despite the improved tolerability of 
SSRIs over other antidepressants, such as monoamine oxidase inhibitors and tricyclic 
antidepressants, they have a slow onset of response and about one third of individuals 
treated with SSRIs are considered non-responders 135,136. Therefore, the development of 
new antidepressant pharmacotherapies continues to be of importance in improving the 
lives of those who suffer from MDD. 
 
1.7 HABITUATION AND EXTINCTION MECHANISMS 
 
The hemodynamic response to presentations of emotionally valenced stimuli 
follows a biphasic pattern of activation in healthy individuals.  For example, fMRI 
studies have shown that the amygdala is activated during the initial period of 
exposure to fear-conditioned stimuli, but then becomes deactivated (or habituated) 
during repeated exposures to the same stimulus. Eventually, through the process of 
extinction, the activity decreases to below the baseline BOLD signal level 61,62,137.  
While the amygdala is postulated to play a key role fear conditioning, the PFC has 
been implicated in the extinction process of responses to emotionally valenced 
stimuli. For example, a study of animal phobics showed orbital CBF was unchanged 
during the initial exposures to phobic stimuli when fear was the greatest, but as 
habituation occurred, posterolateral orbital CBF increased, inversely correlating with 
measures of heart rate and changes in anxiety ratings 138. In addition to paradigms 
with phobia-related components, evidence of amygdala habituation of the BOLD 
signal response has been found with multiple presentations of affective facial 
expressions in healthy individuals 64,97,139.   
 
In mood-disordered individuals, habituation and extinction of hemodynamic 
response patterns involving both the amygdala and prefrontal cortical areas are of 
unique interest given the finding that these individuals do not normally habituate to 
the presentation of certain emotional stimuli. In a study by Drevets et al. 98, the 
hemodynamic response to initial exposures of sad faces presented to individuals with 
MDD and bipolar disorder (BD) did not differ from control subjects, however 
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repeated presentations of these sad faces resulted in habituation of the response in the 
controls, but not depressed individuals. The increased amygdala CBF was sustained 
across continued presentations of the sad faces in the depressed individuals.  This 
effect has also been found during the presentation of negatively valenced words 
presented to depressed and control individuals. During exposure to negatively 
valenced words, increases in amygdala hemodynamic activity were found in both 
groups, however the response persisted abnormally in the depressed individuals and 
normalized in controls 140. This phenomenon of sustained amygdala activity in MDD 
in response to emotionally valenced stimuli is of particular importance given 
evidence that the amygdala is involved in acquisition and expression of emotional 
information (e.g. aversive conditioning) 60,141,142. If proper PFC functioning is 
necessary to extinguish learned emotional responses, it is plausible that the increased 
amygdala response would excessively stimulate cortical areas. This may lead to the 
tendency of depressed individuals to ruminate on memories of emotionally aversive 
or guilt-provoking life-events, possibly due to a dysfunction in the reciprocal 
interactions of the PFC and amygdala in the modulation of emotional responses 66. 
Furthermore, these emotional responses may be generated and maintained on a 
subconscious level, outside explicit cognitive awareness. 
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2 AIMS 
 
The objective of the present thesis was to elucidate and understand the role of 
neurophysiological abnormalities associated with non-conscious emotional 
processing in major depressive disorder (MDD) using functional magnetic 
resonance imaging (fMRI). 
 
The primary aims of the project were as follows: 
 
1. To pilot a novel fMRI backward masking task in healthy controls designed to 
present emotional face stimuli below the level of explicit conscious awareness. 
 
2. To compare differences in neural responses to non-consciously presented sad, 
happy and neutral face stimuli between healthy controls and patients with 
current MDD. 
 
3. To compare differences in neural responses to non-consciously presented 
emotional face stimuli in an unpaired, cross-sectional study design between 
patients with MDD in full remission and patients with current MDD. 
 
4. To assess the effects of antidepressant treatment with the selective serotonin 
reuptake inhibitor, sertraline, on neural responses to emotional face stimuli in 
patients with current MDD. 
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3 MATERIALS AND METHODS 
 
3.1 PARTICIPANTS 
 
3.1.1 Recruitment and Selection Procedure 
 
In Paper I, 25 healthy controls (HC; 15 female, aged 28.8 (± 6.7 years), 22 
unmedicated participants with major depressive disorder in a current depressive 
episode (dMDD; 12 female, aged 31.1 ± 7.8 years) and 16 unmedicated participants 
with major depressive disorder in full remission (rMDD; 11 female, aged 30.8 ± 9.8 
years) were recruited from the National Institute of Mental Health (NIMH) Mood and 
Anxiety Disorders Program and the National Institutes of Health inpatient and 
outpatient clinical services, Bethesda, Maryland, USA.  In some cases these 
individuals were recruited using advertisements posted in the Washington D.C. 
metropolitan area, as approved by the NIMH Human Studies Committee.  All 
participants were right-handed and between the ages of 18-50 years old. The race 
distribution of the samples in the study was similar to that of the greater Washington 
D.C. metropolitan area. 
 
In Paper II, additional analyses were performed on the data acquired from the 
25 HC and 22 dMDD participants described in Paper I.  
 
In Papers I and III, 10 of the 22 dMDD participants (6 female, aged 33.2 ± 5.0 
years) underwent antidepressant treatment with the selective serotonin reuptake 
inhibitor, sertraline, and completed the fMRI task before and after eight weeks of 
pharmacotherapy. Ten of the 25 HC participants (7 female, aged 28.4 ± 5.7 years) 
also completed the fMRI task before and after an equivalent eight-week time period.  
 
3.1.2 Inclusion and Exclusion Criteria 
 
Prior to enrollment in the study, the individuals participated in a phone screen 
and in-person screening evaluation at the National Institutes of Health to determine 
eligibility. The screening health evaluation included a medical and psychiatric history, 
current medication and pharmacotherapy history, laboratory testing (including 
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hematology, blood chemistry, thyroid function, urinalysis, urine drug screen and HIV 
testing), pregnancy test for women, electrocardiogram, physical examination and 
neuromorphological MRI. The psychiatric diagnosis was established by the Structured 
Clinical Interview for DSM-IV (SCID). 143 with a clinician and a semi-structured 
interview with a psychiatrist. A family history of psychiatric disorders was established 
by the Family Interview for Genetic Studies (FIGS) 144. 
 
Healthy Volunteers: Individuals were selected who did not meet criteria for any 
major psychiatric disorder, had no known first-degree relatives with mood disorders, 
and whose current score on the Hamilton Depression Rating Scale (HAM-D; 24-item) 
was in the non-depressed range (≤ 7) 145. 
 
dMDD Participants: Individuals were selected with primary MDD in a current 
major depressive episode who met the Diagnostic and Statistical Manual of Mental 
Disorders-IV-TR 2 criteria for major depressive disorder and whose current HAM-D 
score was in the moderately-to-severely depressed range (≥ 19) 145. The participants 
were drug-naïve or had not received psychotropic drugs for at least 3 weeks (8 weeks 
for fluoxetine) prior to scanning.  Effective medications were not discontinued for 
purposes of the study.   
 
rMDD Participants: Individuals were selected with a past history of MDD in 
current remission by DSM-IV criteria 2. Effective medications were not discontinued 
for the purposes of the study and participants were medication-free and in remission for 
a minimum of three months prior to scanning. 
 
Individuals were excluded if they had a) serious suicidal ideation or behavior, 
b) psychosis to the extent that the ability to provide informed consent was in doubt, c) 
medical conditions or current medications that were likely to influence cerebral blood 
flow or neurological function including cardiovascular, respiratory, endocrine and 
neurological diseases, d) a history of drug or alcohol abuse within 1 year or a lifetime 
history of alcohol or drug dependence 2, e) current pregnancy (as documented by 
pregnancy testing prior to scanning), f) general MRI exclusion criteria, g) a history of 
non-response to sertraline or of intolerable or adverse side effects during sertraline 
treatment.  Additional exclusion criteria applied to control participants were:  a) a 
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current or past history of axis I psychiatric conditions, b) a first-degree family member 
with current or past history of mood disorder.   
 
Individuals beyond age 50 were excluded from the study to reduce the 
biological heterogeneity encompassed by the MDD criteria, and to reduce the 
variability of the BOLD signal 146.  Participants whose first major depressive episodes 
arose after other major medical or psychiatric conditions were also excluded, since their 
functional imaging results generally differ from those reported in primary MDD 24. 
 
3.1.3 Antidepressant Drug Treatment 
 
Ten dMDD participants underwent treatment with the antidepressant drug 
sertraline hydrochloride (50 mg/d for 3 days and then titrated to 100 mg/d as 
tolerated). Each person completed a pre-treatment fMRI scan and follow-up post-
treatment scan after eight weeks of pharmacotherapy. Ten HC participants completed 
the fMRI task before and after the same time interval to control for test-retest and 
other non-specific order effects. Under the supervision of the study psychiatrist, the 
sertraline dose was increased or decreased as clinically indicated. Participants 
received a constant dose for at least four weeks prior to the post-treatment fMRI scan. 
The mean (SD) dose was 105 (50) mg/d (range, 50-200 mg/d) at the time of the post-
treatment scan. Participation in the antidepressant treatment was voluntary and not 
required for enrollment in the study. An interim analysis between HC and dMDD 
groups was performed to validate the fMRI task prior to the start of the treatment 
portion of the study. Following the task validation, all dMDD participants who 
enrolled in the study were presented with the treatment option. Individuals who 
declined treatment were still eligible to participate in the first fMRI scan.  
 
3.1.4 Patient Monitoring and Withdrawal Criteria 
 
Successful antidepressant drug treatment was not discontinued for participants 
with MDD to be included in the study.  Upon entering the study, participants were 
permitted to remain unmedicated for up to two weeks for the purpose of obtaining the 
fMRI scan in the unmedicated condition.  Although individuals with dMDD who 
expressed serious suicidal ideation at entry were excluded, participants were 
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monitored by a health care professional during the two-week time period to monitor 
suicidal ideation and the potential for worsening of depressive symptoms. 
   
While no suicidal ideation developed for the participants of this study, the 
plan for participants who became suicidal or developed clinically serious 
exacerbations of their clinical condition involved exclusion from further participation 
and an evaluation of the need for more intensive management or inpatient 
hospitalization either at the National Institutes of Health or under the care of their 
own physician. Following the post-treatment scan, dMDD participants were referred 
to treatment trials being offered by the NIMH. Participants who were either ineligible 
or unwilling to participate in such protocols were referred to a private mental health 
professional (e.g. psychiatrist).  Participants were treated as clinically appropriate and 
stabilized in the transition between finishing the study and being discharged from the 
NIMH clinic for a period of up to three months. 
 
During the treatment period of the study, participants were evaluated on a 
weekly basis for clinical progress, side/adverse effects, compliance, and development 
of clinical manifestations such as suicidal ideation or hypomania.  During the latter part 
of the treatment period dMDD participants who were psychiatrically stable and 
clinically improved were evaluated biweekly.  Participants were asked to contact the 
study psychiatrist before discontinuing the sertraline trial. Abrupt discontinuation of 
sertraline may have resulted in adverse effects such as depressed, anxious, irritable or 
fluctuating mood, restlessness, fatigue, insomnia, tingling or prickling sensations on the 
skin, dizziness, or headache. Participants were provided with contact information in 
case of emergency through which they could receive medical care from a physician at 
any time.    
 
3.1.5 Human Subjects Protection 
 
3.1.5.1 Consent Process 
 
All volunteers asked to participate in the study were informed that no 
immediate personal or medical benefit would be derived from participation.  fMRI was 
described as a research tool with the potential to benefit individuals with similar 
illnesses in the future, but at the present time was not helpful for indicating treatment, 
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diagnosis, or prognosis.  Participants were also informed of all potential risks involved 
in their participation.  They were reminded that participation was completely voluntary 
and they could withdraw from the study at any time. Informed consent was documented 
using specific forms for each study group, reviewed and approved by the National 
Institute of Health Combined Neuroscience Institutional Review Board. The research 
was conducted under protocol 04-M-0002 entitled “The Functional Neuroanatomy of 
Emotion Regulation in Major Depressive Disorder”.  Informed consent was obtained 
by the principal investigator or a designee.  Participants were required to read the 
informed consent form and the investigator additionally described all aspects of the 
study procedure. The consent documents included a payment schedule for participation 
in the study. All subjects were compensated for their time commitment for completing 
the interviews, neuropsychological testing, ratings scales, physical exam, fMRI scans, 
and follow-up visits during antidepressant treatment. 
 
3.1.5.2 Evaluation of Benefits and Minimization of Participation Risks 
 
The research study consisted primarily of the performance of non-invasive 
brain imaging procedures.  Participants underwent MR imaging, which involved laying 
still for up to 90 minutes, but no other risks or discomforts. No known hazards exist for 
the exposure of magnetic waves during MR imaging.  However, there is a potential risk 
of heart rhythm disturbances in patients with previous heart rhythm abnormalities or 
with certain types of pacemakers and a substantial risk to persons who have metallic 
objects inside their bodies.  
 
The potential risks related to MRI were minimized in the following manner: 1) 
Claustrophobia from MRI, due to having one’s head confined in a relatively small 
space, was reduced by explaining the nature of the MRI scanner in detail to all 
participants prior to their enrollment in the study.  Participants who had a history of 
significant claustrophobia were not entered into the study and if it occurred, the study 
was terminated at the subject’s request. 2)  A possible history of any intraocular, intra-
aural, intracranial, or intrathoracic metal excluded the subject from the study.  3) A 
radiology technologist was present throughout the MRI scan and a physician was 
available in the vicinity of the MRI facility for medical emergencies. 4) Pregnant 
women were excluded from the study because of unknown effects on the fetus. 
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Participant confidentiality was maintained by keeping all clinical records in 
locked filing cabinets and password-protected computer files.  MRI scan files were 
identified by a number, and associated names were kept in a confidential file accessible 
to only specified personnel with legitimate scientific interests.  Image files that included 
experimental details were maintained in filing systems accessible only to the physicians 
and other technical staff working in the MRI laboratory. 
 
In summary, the fMRI, clinical and psychological assessments involved in the 
study posed no more than minimal risk to participants.  The treatment phase of the 
study with sertraline involved a minor increase over minimal risk due to the delay of 
treatment by up to two weeks for the depressed individuals described above.  However, 
sertraline had the potential to provide benefit to the depressed participants by providing 
treatment for major depression.  By increasing understanding of pathophysiology, the 
research study proposed the possibility to improve treatment modalities, diagnostic 
capabilities, and classification systems and also to aid in de-stigmatizing psychiatric 
illness and convincing noncompliant persons that medications were likely to be helpful.  
The importance of the knowledge to be gained from this study clearly exceeded the 
associated potential risks. 
 
3.2 BACKWARD MASKING TASK DESIGN 
 
A novel fMRI task was developed using the technique of backward masking 
and a slow-event related design to assess neurophysiological responses to emotional 
face stimuli presented below the level of conscious awareness. In the scanner, 
participants were shown two neutral target face stimuli at the beginning of each of 
four 10-minute task runs. They were instructed to remember the target faces for the 
duration of the run. When the run began, faces appeared on the screen in pairs of two, 
displaying a masked face for 26 ms immediately followed by an unmasked face for 
107 ms to inhibit conscious detection of the first face. Participants were unaware of 
the masking component of the task. They were asked to use a button box with their 
right hand to make a decision as quickly as possible about each face that appeared on 
the screen. If the face they perceived was a target face, they pressed the “1” (top) 
button. If the face was not a target, they pressed the “2” (bottom) button. The faces 
displayed neutral, sad or happy expressions and participants judged whether or not 
the face was a target based on the identity of the original two neutral target faces, not 
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the depicted emotional expression. Prior to entering the scanner, participants 
confirmed their understanding of the task by performing an abbreviated version of the 
task using flash cards. 
 
By design, an emotional face stimulus was presented in the masked position 
and followed by a neutral stimulus for the sad-neutral (SN), happy-neutral (HN) or 
neutral-neutral (NN) face pairings. In addition, a neutral face stimulus was presented 
in the masked position and followed by an emotional face stimulus for the neutral-sad 
(NS) and neutral-happy (NH) face pairings. A sad or happy face stimulus in the 
masked position was never also presented in the unmasked position (i.e. the identity 
of the emotional face was different). Within a single trial, the identity of the masked 
face was never the same as the identity of the unmasked face, but the two face stimuli 
always depicted the same gender. The gender for all stimulus pairings was balanced 
across runs. The SN, HN, NS, and NH stimulus pairings were each presented eight 
times each and the NN pairings were presented 16 times each within a single run in a 
pseudo-randomized, mixed-trial design. Each run used different target faces and 
emotional face stimuli from distinct actors. The data from the four runs were 
combined so that each stimulus pairing was presented a total of 32 times for pairs that 
included an emotional face and 64 times for pairs including only neutral faces. A 10-
13s interstimulus interval was selected to allow the hemodynamic response to return 
to baseline prior to the next stimulus pair presentation. For participants who 
performed the task before and after an 8-week treatment interval, unique emotional 
face stimuli were used for each scanning session. 
 
The backward masking task and behavioral response collection was 
programmed and controlled via E-Prime on a Monarch Hornet computer with a 
cathode ray tube monitor at 75 Hz and a cloned projection display that was time-
linked to the image acquisition in the scanner. The face images were projected onto a 
screen in the scanner that was easily visible to subjects in the scanner gantry using a 
mirror system. Presentation time accuracy for the masked and unmasked face images 
were verified using a photodiode and oscilloscope. Face stimuli for the backward 
masking task were obtained from the NimStim Set of Facial Expressions 147 and 
modified to change the images from color to black and white, to display only the face 
(excluding clothing and hair) and to align the images at the level of the eyes to 
maintain consistency between the images. 
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Figure 1. Example images from the backward masking task design. Neutral face 
placeholders are shown instead of neutral faces, due to restrictions on the publication 
of images from the NimStim Set of Facial Expressions. 
 
 
 
3.3 PSYCHIATRIC AND NEUROPSYCHOLOGICAL ASSESSMENTS 
 
Study participants completed a battery of interviewer-based and paper and pencil 
rating scales for psychiatric and neuropsychological assessment (listed below). Data 
obtained from the assessments were analyzed using SPSS version 14.0 statistical 
software. Analysis of variance (ANOVA) and t-tests were used to compare differences 
in scores (e.g. on the Hamilton Depression Rating Scale) between dMDD, rMDD and 
HC participants, as well as differences before and after anti-depressant treatment in 
dMDD participants (or the equivalent time period for HC participants). Additional 
analyses were conducted to assess whether these scores correlated with changes in the 
hemodynamic response to emotional stimuli obtained from the functional imaging 
analyses in individuals with dMDD. 
 
3.3.1 Interviewer Assessment Scales 
 
Structured Clinical Interview for DSM (SCID):  The SCID is a structured interview 
used to determine major DSM Axis 1 diagnoses in adults 143.  
 
Family Interview for Genetic Studies (FIGS):  The FIGS is a semi-structured 
assessment designed to evaluate family history of psychiatric illness 144. 
 
Hamilton Depression Rating Scale (HAM-D): The HAM-D is a clinician-administered 
rating scale designed to assess the severity of depressive symptoms 145.   
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3.3.2 Self-Report Assessment Scales 
 
Automatic Thoughts Questionnaire (ATQ): The ATQ is a self-report rating scale 
designed to measure the frequency of negative thoughts 148. 
 
Thought Control Questionnaire (TCQ):  The TCQ is a self-report rating scale designed 
to assess an individual’s ability to control negative thinking 149.  
 
State-Trait Anxiety Inventory (STAI): The STAI is a self-report rating scale used to 
assess state-dependent and trait characteristics of anxiety 150. 
 
The Inventory of Depressive Symptomatology (IDS): The IDS is a self-report rating 
scale used to assess an individual’s view of their depression 151. 
 
Edinburgh Handedness Inventory (EDI): The EDI is a self-report laterality scale used 
to estimate the degree of right or left hand dominance during everyday activities 152. 
 
3.3.3 Neuropsychological Assessment Scales 
 
Wechsler Abbreviated Scale of Intelligence (WASI):  The WASI is a 15 minute 2-
subtest index of estimated general intelligence normed for ages 6 – 89 153. 
 
Cambridge Neuropsychological Test Automated Battery (CANTAB):  The CANTAB is 
a computer-based cognitive assessment system consisting of 22 neuropsychological 
tests, administered to subjects using a touch screen computer. 
 
3.4 BEHAVIORAL DATA ACQUISITION AND ANALYSIS 
 
Participants were debriefed following completion of the fMRI scan and asked 
about their experience of performing the task in the scanner. Reaction time (RT) and 
accuracy data for detection of each face stimulus as “target” or “non-target” were 
recorded via the E-Prime software used to present the backward masking task. Each 
participant response was classified into one of four categories according to target 
detection accuracy: correction detection, correct rejection, incorrect detection (false 
alarm rate) and incorrect rejection. Behavioral accuracy data were analyzed using SPSS 
version 14.0 statistical software. ANOVA and t-tests were used to explore differences 
between groups and response categories to target faces presented in the masked 
position and to explore differences in reaction time to target masked-sad and masked-
happy faces. 
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3.5 FUNCTIONAL AND ANATOMICAL MRI DATA ACQUISTION 
 
Images were collected on a General Electric 3.0 Tesla scanner (GE Signa, 
Milwaukee, Wisconsin) with an 8-channel phased-array head coil. The parameters for 
the echo planar imaging (EPI) included: continuous axial slices = 39, echo time (TE) = 
20ms, repetition time (TR) = 2000 ms, flip angle = 90°, matrix size = 64 x 64, field of 
view = 22 cm, and voxel dimensions = 3.4 x 3.4 x 3.0 mm3. A total of 290 fMRI 
images were acquired in each of four 10-minute runs during the backward masking 
task. Four images were discarded from the beginning of each run to allow for steady-
state tissue magnetization. The parameters for the anatomical images included: a fast 
spoiled gradient echo (FSPGR) sequence, TR = 780 ms, TE = 2.7 ms, flip angle = 12º, 
FOV = 22 cm, matrix= 224 x 224, 128 axial slices, 1.2 mm thick, in-plane resolution = 
0.98 mm2.  
  
3.6 FMRI DATA PROCESSING AND ANALYSIS 
 
Functional imaging analyses were performed using the general linear model 
within the SPM5 statistical imaging software (Wellcome Trust Center for 
Neuroimaging, London, England). Each participant’s whole brain EPI data were 
realigned, co-registered to the anatomical image, and normalized to fit the Montreal 
Neurological Institute (MNI) standard brain template and smoothed with a Gaussian 
filter (8 mm, full-width at half-maximum). Motion artifacts were modeled into the 
analysis as regressors to correct for movement. An fMRI run was excluded from the 
analysis if the subject showed movement of more than one-half voxel (1.5 mm) 
translation or 1.25° rotation. Data from a minimum of three runs were included for each 
participant. Following the statistical analyses, coordinates were transformed from MNI 
to the stereotaxic array of Talairach and Tournoux 154. Anatomical localization was 
performed using the Mai et al. 155 and Talairach and Tournoux 154 stereotaxic atlases. 
 
3.6.1 Paper I 
 
Single-subject t-contrast maps were generated by comparing the difference 
between conditions (e.g. SN-HN: masked-sad versus masked-happy faces, SN-NN: 
masked-sad versus masked-neutral faces, and HN-NN: masked-happy versus masked-
neutral faces). At the group level, beta-weight values obtained from the single-subject 
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analyses were evaluated for significant differences within an amygdala region-of-
interest (ROI) using “small volume correction”. The reported results remained 
significant after applying a false-discovery rate error correction or consisted of a cluster 
of ≥10 contiguous voxels at a threshold of p<0.05 (uncorrected). An exploratory brain 
analysis was performed post-hoc for regions outside the amygdala and results included 
regions with a cluster of ≥10 contiguous voxels at a threshold of p<0.001.  
 
In Experiment 1, dMDD and HC participants were compared using two-sample 
t-tests to evaluate the difference in the hemodynamic response of the amygdala between 
groups for masked-sad versus masked-happy faces. Post-hoc t-tests also evaluated 
differences in the amygdala response to SN-NN and HN-NN. Finally, the 
hemodynamic response between dMDD and HC participants was compared for 
unmasked-sad versus unmasked-happy faces. Beta-weights were extracted at the peak 
voxels within the left and right amygdala region-of-interest. 
 
In Experiment 2, rMDD participants were compared to dMDD and HC 
participants. A repeated-measures ANOVA was used to analyze hemodynamic 
differences across conditions (SN, HN, NN) and groups (dMDD, rMDD, HC). 
Independent t-tests were performed post-hoc and beta-weights were extracted at the 
peak voxel within a cluster to characterize specific interaction effects. 
 
In Experiment 3, ten dMDD participants were rescanned after 8 weeks of 
sertraline treatment and 10 HC subjects were rescanned following the same time 
interval. Paired t-tests were used to compare the hemodynamic response of the 
amygdala in dMDD participants before and during treatment for each emotional face 
condition. A time x group (MDD, HC, pre- vs. post-) ANOVA was conducted to 
evaluate differences in the response to SN-NN across the treatment interval.  
 
3.6.2 Paper II 
 
Single-subject t-contrast maps for HC and MDD were generated by 
comparing the difference between the emotional conditions (SN, HN, NN) and  
baseline (crosshair). A 2x3 (group x emotion) ANOVA was performed to analyze 
regional hemodynamic differences across conditions. Within the group x emotion 
model, t-tests were performed to characterize the specific contrasts that accounted for 
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the interactions (i.e. SN-HN, SN-NN, and HN-NN). Eigenvariate values were 
extracted from each significant cluster’s peak voxel. The reported results remained 
significant at a height threshold for the peak voxel in a cluster at puncorrected≤0.001 and 
a minimum cluster size of k=23 voxels, as determined using the AlphaSim program 
within the Analysis of Functional Neuroimages (AFNI) software. Regions that 
remained significant after applying this correction were noted in the tables with an 
asterisk. To maintain continuity with the Paper I results that reported on the amygdala 
region-of-interest analysis, additional regions were included in the tables that 
remained significant at puncorrected≤0.001 with a minimum cluster size of 10 voxels.  
 
3.6.3 Paper III 
 
A paired samples t-test was used to evaluate regional hemodynamic response 
differences between pre-treatment and post-treatment fMRI scans for the SN-HN 
contrast. The significance threshold was set at puncorrected≤0.001 for the peak voxel 
within each cluster, with a minimum cluster size of 10 voxels, to provide continuity 
with Papers I and II. To correct for multiple comparisons, a minimum cluster size of 
k=23 voxels was applied, as determined using the AlphaSim program within AFNI. 
These regions were noted with an asterisk in the Paper III tables. Beta-weights were 
extracted from the peak voxel within the cluster-level corrected region identified in the 
SN-HN contrast and compared across conditions.  
 
Additional post-hoc t-tests were performed to evaluate regional differences in 
the hemodynamic response to SN-NN and HN-NN, independently of the SN-HN 
comparison.  The reported results included regions with a minimum cluster size of 
k=23 voxels in conjunction with a peak voxel t-value of puncorrected≤0.001. 
 
 Independent t-tests were performed for the SN-HN contrast to evaluate 
differences between dMDD and HC subjects after the 8-week treatment interval. 
Results were reported in parallel with the SN-HN contrast described above for only 
dMDD participants. An amygdala region-of-interest analysis was performed using the 
“small volume correction” option within SPM5 (p<0.05, minimum k=10 voxels). 
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4 RESULTS AND DISCUSSION 
 
4.1 RELATIONSHIP BETWEEN AMYGDALA RESPONSES TO MASKED 
FACES AND MOOD STATE AND TREATMENT IN MDD (PAPER I) 
 
4.1.1 Characteristics of the Study Participants  
 
No significant differences were found between the HC, rMDD and dMDD 
groups with respect to gender composition, mean age and mean intelligence scores.  
 
Of the 22 dMDD participants, 4 were diagnosed with a chronic, single episode 
of MDD and 19 with recurrent MDD. 13 had no co-morbid psychiatric diagnoses, 
while 5 were diagnosed with MDD and social anxiety disorder (SAD), 3 with MDD 
and panic disorder, 1 with MDD, SAD and dysthymic disorder, and 1 with MDD, post-
traumatic stress disorder (PTSD) and simple phobia. 13 participants were naïve to drug 
treatment. The mean age of onset of depressive symptoms for the dMDD group was 
16.7 ± 6.0 years. 
 
Of the 16 rMDD participants, 5 were diagnosed with a past history of a single 
episode of MDD in full remission and 11 with recurrent MDD in full remission. 13 
participants had no co-morbid psychiatric diagnoses, while 1 was diagnosed with 
rMDD and past alcohol abuse, 1 with rMDD, SAD in remission and past alcohol abuse, 
and 1 with rMDD and PSTD in remission. 3 participants were naïve to drug treatment. 
The mean age of onset for the rMDD group was 18.3 ± 4.3 years. 
 
For the subset of 10 dMDD participants who participated in the sertraline 
treatment portion of the study, 1 was diagnosed with a chronic, single episode of MDD 
and 9 with recurrent MDD, 8 had no co-morbid psychiatric diagnoses, 1 was diagnosed 
with MDD and SAD, and 1 with MDD, PTSD and simple phobia. 4 were treatment 
naïve.  The mean age of onset was 18.6 ± 5.6 years. 
 
4.1.2 Psychiatric Assessment Scales 
 
For the 22 dMDD, 16 rMDD and 25 HC participants, the mean (SD) HAM-D 
score was 24.0 ± 6.3, 1.0 ± 1.4 and 0.0 ± 0.2, respectively. dMDD participants scored 
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greater than HC participants on the HAM-D, ATQ, IDS-SR, STAI, and 3 subscales of 
the TCQ (all p<0.001). dMDD participants scored greater than rMDD participants on 
the HAM-D, ATQ, IDS-SR, STAI (all p<0.001), and 3 subscales of the TCQ (all 
p<0.05). rMDD participants scored higher than HC participants on the HAM-D 
(p<0.005), ATQ (p<0.005), IDS-SR (p<0.05), and STAI-Trait scale (p<0.001). 
 
For the subset of 10 dMDD participants who underwent treatment, dMDD 
participants significantly decreased their scores on the HAM-D from the pre-treatment 
(24.8 ± 5.8) to the post-treatment condition (6.4 ± 6.0) (p<0.001). Additionally, scores 
decreased in the dMDD-post vs. dMDD-pre condition on the ATQ, IDS-SR, STAI-
Trait scale (all p<0.001) and STAI-State scale, and 2 subscales of the TCQ (all p<0.05).  
The mean HAM-D score was 0.0 (0.0) for the HC participants in both the pre- and 
post-treatment conditions. 
 
4.1.3 Antidepressant Pharmacotherapy Efficacy  
 
Nine of the 10 dMDD participants reached the clinical definition of a treatment 
responder by the end of the eight-week period (HAM-D score reduction of ≥ 50%). 
Seven out of 10 entered full remission from their symptoms during treatment (HAM-D 
score ≤ 7). Despite the significantly decreased HAM-D scores, the dMDD-post scores 
remained higher than rMDD participants on the HAM-D and IDS-SR (p<0.01) and 
ATQ, STAI and 2 subscales of the TCQ (all p<0.05). 
 
4.1.4 Behavioral Results 
 
4.1.4.1 Reaction Time 
 
A significant difference in reaction time was revealed between HC, rMDD and 
dMDD participants for sad faces in the masked face position (p<0.001).  Post-hoc tests 
showed rMDD participants responded faster to masked-sad faces than both dMDDs 
(p<0.05) and HCs (p<0.001).  Consistent with and in support of the neuroimaging 
results shown in the amygdala (see section 4.1.5), dMDD participants responded faster 
to target masked-sad faces than HCs (p<0.05) and HCs responded faster to target 
masked-happy faces compared to target masked-sad faces (p<0.001). 
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4.1.4.2 Task Efficacy 
 
Participants were debriefed upon completion of the fMRI task and questioned 
about their subjective experience in the scanner. No participant reported conscious 
awareness of the backward masking procedure (i.e. they did not endorse seeing 2 faces) 
during the fMRI scan. An objective measure of each participant’s awareness involved 
an examination of the accuracy data obtained during the backward masking task. 
Participants did not differ in the accuracy of their response to a target face in the 
masked position (24.4 % correct detection)  versus when no target face was presented 
in either face position (25.4% incorrect detection or false-alarm) (p=0.88).   These 
results provide evidence that the experimental task was successful at inhibiting 
conscious perception of the masked face stimuli. 
 
4.1.5 fMRI Results 
 
The following results highlight significant hemodynamic response differences 
within an amygdala region-of-interest analysis to masked-sad vs. masked-happy faces 
(SN-HN), masked-sad vs. masked-neutral faces (SN-NN) and masked-happy vs. 
masked-neutral (HN-NN) faces between dMDD, rMDD and HC participants, as well as 
the effect of sertraline treatment on the amygdala response to emotional face stimuli. 
 
In Experiment 1, the left and right amygdala hemodynamic response to masked-
sad vs. masked-happy faces (SN-HN) was significantly greater in dMDD vs. HC 
participants (t45=3.00, p<0.005 and t45=2.80, p<0.005, respectively) and remained 
significant following correction for multiple comparisons (p<0.05, bilaterally) (Figure 
2a). Figures 2b-d illustrate the magnitude of the difference between groups for SN-HN 
and corresponding differences in SN-NN and HN-NN at the peak voxel coordinate for 
the SN-HN comparison. Specifically, the bilateral amygdala response to SN-HN and 
SN-NN was greater in dMDD participants than HCs (p<0.005). In contrast, the left 
amygdala response to HN-NN was greater in HCs than dMDDs (p<0.01), replicating 
previous findings that report an increased amygdala response to masked-happy faces 
relative to either fixation or neutral faces 113,114  An exploratory whole brain analysis for 
SN-HN showed a greater response in the hippocampus (t45=3.91, p<0.001) in dMDDs 
than HCs and in contrast, a greater response in the thalamus in HCs than dMDDs 
(t45=3.52, p<0.005). An additional whole brain analysis revealed no significant 
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difference between groups in the amygdala for unmasked-sad vs. unmasked-happy 
faces (NS-NH). 
 
Figure 2. (a) Activation map illustrating a significant difference between dMDD and 
HC participants to masked-sad faces vs. masked-happy faces (SN-HN). Arrows refer to 
the left amygdala (x= -26, -7, -16) and right amygdala (x= 26, -1, -12). (b-d) Beta-
weight contrasts for the peak voxel coordinates in the SN-HN comparison.  
 
 
 
These amygdala findings are consistent with evidence that the amygdala is 
selectively tuned toward the detection of biologically salient information 52. The 
amygdala receives projections from both the sensory cortices that facilitate explicit 
perception and subcortical cortical structures that allow for rapid non-conscious 
assessment of stimulus characteristics 53,60. This rapid response system can detect 
information that is novel, threatening, rewarding or socially significant in the amygdala, 
including faces. Our results show that non-conscious presentations of emotional 
information show differential amygdala response biases dependent upon the social 
significance of the stimuli and current mood-state (i.e. either healthy or currently 
depressed). The lack of an amygdala response difference in unmasked faces suggests 
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that presenting emotional faces below the level of conscious awareness may be 
advantageous in the identification of processing biases in the amygdala. This method 
may provide an enhanced sensitivity for identifying differences in response patterns 
between groups to emotionally salient information.   
 
The main behavioral correlation analysis revealed a significant inverse 
relationship between depression severity (HAM-D score) and the hemodynamic 
response of the amygdala, such that the response to HN-NN decreased as depression 
severity increased (r=-0.45; p<0.05; Figure 3).  This result provides evidence that the 
amygdala response to non-consciously presented stimuli can be influenced by the 
severity of the current mood-state. In addition, the amygdala response showed a 
significant inverse correlation with reaction time, such that the hemodynamic response 
to SN-HN increased as reaction time to target masked-sad faces decreased (r=-0.53; 
p<0.05).  
 
Figure 3. The correlation between depression severity and the right amygdala response 
to masked-happy versus masked-neutral faces in dMDD participants (HN-NN). 
 
In Experiment 2, an ANOVA  revealed a significant condition (SN, HN, NN) 
by group (dMDD, rMDD, HC) interaction in the left amygdala (Figure 4a). The left 
amygdala hemodynamic response to masked-sad vs. masked-happy faces was greater 
in the dMDD and rMDD participants compared to HC participants (Figure 4b). There 
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were no differences shown between dMDD and rMDD participants. These results 
suggest evidence of a negative emotional processing bias that persists independently of 
the current mood-state in major depressive disorder.  This “illness-congruent” finding 
for individuals in remission may suggest a potential biomarker of relapse vulnerability 
and likelihood for the recurrence of clinically significant depressive symptoms. 
Interestingly, rMDD participants showed increased trait anxiety and automatic negative 
thought patterns compared to HC participants, symptoms that appear endophenotypic in 
the development of MDD 156. 
 
Figure 4. (a) Activation map illustrating a significant difference between groups by 
emotion in the left amygdala. Arrow refers to the left amygdala (x= -26, y= -5, z= -16). 
(b) Beta-weight contrasts for the peak voxel in the SN-HN comparison. 
 
 
 
In Experiment 3, dMDD participants showed a significant decrease in the right 
amygdala hemodynamic response to masked-sad versus masked-neutral faces (t9=3.26; 
p<0.01) following antidepressant treatment (Figure 5a) with a concomitant significant 
increase in the left amygdala response to masked-happy faces versus masked-neutral 
faces (t9=2.59; p<0.05) (Figure 5b).  Across the treatment interval, an ANOVA 
revealed a significant reduction in the amygdala response to SN-NN in dMDD 
participants (p<0.05), but no reduction in the HC participants (p=0.17).  
 
Previous studies have shown a reduction in the hemodynamic response to 
unmasked sad 99 or fearful faces during treatment 129,157. However, this study was the 
first to show, to our knowledge, that non-conscious processing biases were affected by 
antidepressant treatment in a reciprocal pattern, such that a decreased response to 
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masked-sad faces was combined with an increased response to masked-happy faces. 
These results provide support for the hypothesis that a primary therapeutic mechanism 
of antidepressant treatment may involve the normalization of negative processing 
biases 131,133,134.  
 
Of note, 9 out of 10 of the treatment study participants were considered 
treatment responders. However, an exaggerated response to masked-sad faces has been 
reported in persistently depressed patients receiving antidepressant medication 88. This 
finding suggests that the reduction of negative processing biases in the amygdala may 
depend on treatment effectiveness and may provide support for the maintenance of 
antidepressant treatment, considering the increased response to masked-sad faces 
reported in the thesis work for MDD patients in remission. 
 
Figure 5. Activation maps and coordinating beta-weight contrasts at the peak voxel 
within each cluster illustrating a signifcant difference in dMDD participants before vs. 
after eight weeks of antidepressant treatment in the (a) right amygdala for masked-sad 
versus masked-neutral faces and (b) left amygdala for masked-happy versus masked-
netural faces. 
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4.2 THE EXTENDED FUNCTIONAL NEUROANATOMY OF EMOTIONAL 
PROCESSING BIASES FOR MASKED FACES IN MDD (PAPER II) 
 
4.2.1 fMRI Results 
 
A whole-brain group (dMDD, HC) x emotion (SN, HN, NN) ANOVA revealed 
a significant interaction in the left anterior insula (F2,90=9.63, p<0.001), left rostral 
superior temporal gyrus (rSTG; F2,90=7.62, p=0.001) and left hippocampus (F2,90=7.34, 
p=0.001). Within this model, t-tests provided an evaluation of the specific contrasts that 
accounted for the interactions.  
 
For the SN-HN contrast, the hemodynamic response was greater in dMDD 
versus HC participants in the left hippocampus (t90=3.74, p<0.001, Figure 6a), left 
amygdala (t90=3.20, p=0.001) and right amygdala/anterior inferotemporal cortex 
(t90=3.28, p<0.001). For the SN-NN contrast, the hemodynamic response was greater in 
dMDD versus HC participants in the left and right rSTG (t90=3.84, p<0.001 and 
t90=3.19, p=0.001, Figure 6b) and right anterior orbitofrontal cortex (OFC; t90=3.28, 
p=0.001, Figure 6c). The hemodynamic response was greater in HC versus dMDD 
participants in the left inferior parietal cortex (t90=3.52, p<0.001) and right frontal polar 
cortex (t90=3.43, p<0.001). For the HN-NN contrast, the hemodynamic response was 
greater in dMDD versus HC participants in the left anterior OFC (t90=3.49, p<0.001), 
left anterior insula (t90=4.42, p<0.001), left pregenual anterior cingulate cortex 
(t90=3.35, p<0.001), left and right rSTG (t90=3.29, p=0.001 and t90=3.28, p=0.001), 
right ventral thalamus (t90=3.27, p=0.001) and right postcentral gyrus (t90=3.18, 
p=0.001). The hemodynamic response was greater in the HC versus dMDD participants 
in the left middle occipital gyrus (t90=3.43, p<0.001). 
 
Finally, post-hoc analyses of the relationship between the neuroimaging results 
and clinical assessment scores revealed an inverse correlation between the 
hemodynamic response to HN-NN and depression severity in the right rSTG and left 
anterior insula. In dMDD participants, the response to masked-happy faces decreased 
as depression severity (HAM-D score) increased (r=-0.43, p<0.05 and r=-0.51, p<0.05, 
respectively).  
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Figure 6. Activation maps and coordinating eigenvariate contrasts at the peak voxel 
within each cluster illustrating a significant difference between dMDD and HC 
participants in the (a) left hippocampus for masked-sad versus masked-happy faces (b) 
left rostral superior temporal gyrus for masked-sad versus masked-neutral faces and (c) 
right anterior orbitofrontal cortex for masked-sad versus masked-neutral faces. 
 
 
 
 
 
The whole brain group analysis of SN-HN confirmed our original region-of-
interest findings in the amygdala from Paper I, although the peak coordinates were 
slightly different. The hippocampus was also implicated in a separate whole brain 
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analysis in Paper I. Projections from the hippocampus to the amygdala convey 
information about environmental context during emotional processing and lesions of 
the hippocampus interrupt this neurotransmission 158,159. The hippocampus may be 
important in setting the context for the negative emotional processing biases shown in 
depression, driving the amygdala to differentially respond to sad versus happy stimuli. 
 
The group differences in the amygdala, hippocampus, superior temporal gyrus 
and right anterior orbitofrontal cortex showed both an increased hemodynamic 
response to masked-sad faces vs. masked-happy or masked-neutral faces in depressed 
individuals combined with a decreased hemodynamic response to masked-sad faces in 
healthy controls (Figure 6a-c).  Projections from these regions to the amygdala convey 
information regarding context, sensory integration and stimulus salience to modulate 
behavioral, emotional and visceral responses 8,12,159,160. In contrast, the superior 
temporal gyrus, left anterior orbitofrontal cortex, insula, pregenual anterior cingulate 
cortex, thalamus and postcentral gyrus showed an increased hemodynamic response to 
masked–happy faces in dMDD combined with a decreased hemodynamic response in 
the healthy controls. This pattern is opposite to that shown in the amygdala. Several of 
these regions form part of the visceromotor network, which has been shown to 
influence the outflow of amygdala response to emotional information and tune cortical 
responses to sensory stimuli 8,12,77.  
 
In combination, these findings provide evidence of a network of structures 
known to participate with the amygdala in the evaluation of the emotional salience of a 
stimulus. In addition, the shared neural circuitry between MDD and HC individuals 
suggests these areas may be differentially processing stimuli dependent upon the 
emotional valence. This network of projections integrates limbic and sensory input and 
may function to maintain an automatic positive processing bias in healthy individuals 
and a negative processing bias in depressed individuals. 
   39 
4.3 CHANGES IN THE NEURAL CORRELATES OF IMPLICIT 
EMOTIONAL FACE PROCESSING DURING ANTIDEPRESSANT 
TREATMENT IN MDD (PAPER III) 
 
4.3.1 Behavioral Results 
 
4.3.1.1 Reaction Time 
 
No differences in reaction time to masked-sad versus masked-happy target 
faces were revealed between HC and dMDD in the pre-treatment fMRI scan or in either 
group between scans.  
 
4.3.1.2 Task Efficacy 
 
Participants were debriefed upon completion of the fMRI task after both the 
pre- and post-treatment scans and questioned about their subjective experience in the 
scanner. No participant reported conscious awareness of the backward masking 
procedure. Response accuracy data obtained during the backward masking task 
revealed no difference in the accuracy of a participant’s response to a target face in the 
masked position (22.8% correct detection)  versus when no target face was presented in 
either face position (22.5% incorrect detection or false-alarm) (p=0.83).    
 
4.3.2 fMRI Results 
 
Paired t-tests revealed the hemodynamic response to masked-sad versus 
masked-happy faces (SN-HN) was greater in the baseline condition compared to the 
post-treatment condition in the right pregenual anterior cingulate cortex (t9=7.79, 
p<0.001, Figure 7), left caudal superior temporal gyrus (t9=6.37, p<0.001) and left 
anterior inferotemporal gyrus (t9=5.17, p<0.001). Post-hoc t-tests in the pregenual 
anterior cingulate region showed the hemodynamic response to SN-NN was greater in 
the pre-treatment versus post-treatment condition (p<0.001, Figure 7). In contrast, the 
hemodynamic response to HN-NN was greater in the post-treatment versus pre-
treatment condition (p<0.05, Figure 7).  
 
Numerous studies have reported findings that the pregenual anterior cingulate 
cortex response changes following antidepressant treatment (e.g. 122,161-163), however 
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our results extend these findings to non-consciously presented emotional stimuli. 
Specifically, we showed that the decrease in response to masked-sad versus masked-
happy faces was attributable to both a reduction in the response to masked-sad faces 
and an enhancement in the response to masked-happy faces (Figure 7). 
 
Figure 7. Activation map and coordinating beta-weight contrasts at the peak voxel 
within the pregenual anterior cingulate cortex for the SN-HN contrast, illustrating a 
significant difference between the dMDD pre- versus post-treatment conditions. 
 
 
 
Exploratory post-hoc analyses for the SN-NN contrast before versus after the 
antidepressant treatment period revealed a greater hemodynamic response in the pre-
treatment condition in several regions of the sensory and visceromotor networks. 
Regions of the visceromotor network share extensive reciprocal connections with the 
amygdala 8,12. Some of the regions within these networks include the pregenual anterior 
cingulate (t9=8.95, p<0.001), bilateral medial thalamus (t9=4.64, p=0.001 and t9=4.29, 
p=0.001), anterior and posterior insula (t9=4.88, p<0.001 and t9=5.46, p<0.001), 
ventrolateral prefrontal cortex (t9=4.21, p<0.001), and medial and lateral orbitofrontal 
cortex (t9=5.06, p<0.001 and t9=4.75, p=0.001). Many of these regions participate in the 
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evaluation of the salience of emotional stimuli and modulation of our experiences and 
behavior 12. 
 
Independent t-tests of the dMDD participants across the treatment interval and 
HC participants across the same time interval for the SN-HN contrast revealed a greater 
hemodynamic response in the dMDD participants relative to controls in the pre- versus 
post-treatment condition in the pregenual anterior cingulate cortex (t18=3.98, p<0.001), 
posterior cingulate cortex (t18=3.72, p=0.001), temporopolar cortex (t18=3.65, p=0.001) 
and amygdala (t18=2.95, p<0.005). In contrast, dMDD participants showed a greater 
hemodynamic response compared to HC participants in the post- versus pre-treatment 
condition in the lateral frontal polar cortex (t18=4.65, p<0.001). 
 
In conclusion, antidepressant treatment with sertraline was associated with 
differential hemodynamic responses to non-conscious emotional stimuli in a network of 
regions of that share extensive anatomical connections with the amygdala. Of particular 
interest, these changes reflect a shift in the pattern of hemodynamic activity in the 
pregenual anterior cingulate cortex and areas of the orbital and medial prefrontal 
network shown prior to treatment. These results were in parallel with our amygdala 
ROI findings observed in Paper I, in which the response to masked-sad faces decreased 
following treatment. In contrast, the opposite pattern was observed for masked-sad 
faces following treatment in the lateral frontal polar cortex, a region shown to modulate 
depression severity (reviewed in 3) and found to show an increased response in HC 
individuals toward masked-sad faces in Paper II. These findings provide further 
evidence to support the hypothesis that a primary therapeutic mechanism of 
antidepressant treatment may involve an alteration in negative processing biases toward 
the positive direction in major depressive disorder 164,165.  
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5 SUMMARY AND CONCLUSIONS 
 
The studies presented in this thesis investigated the role of functional 
neuroanatomical correlates of mood-congruent processing biases toward negative 
information associated with major depressive disorder and differences in neural 
response patterns under antidepressant treatment. We developed a novel backward 
masking technique to evaluate the differential processing of non-conscious emotional 
stimuli in patients with current major depressive disorder, patients with major 
depressive disorder in full remission and healthy volunteers.  
 
In Study I, our results showed behavioral and neurophysiological evidence that 
negative emotional processing biases occur automatically, below the level of conscious 
awareness, in patients with major depressive disorder and that these biases persist 
independently of mood-state in the amygdala. Both unmedicated currently depressed 
and remitted depressed individuals showed an increased hemodynamic response to 
masked-sad versus masked-happy faces. As well, depressed individuals responded 
faster than healthy volunteers to masked-sad faces presented outside conscious 
awareness. In contrast, healthy volunteers showed an increased hemodynamic response 
to masked-happy faces versus masked-neutral faces in the amygdala. The negative 
emotional processing bias shown in depressed individuals resolved while a positive 
bias developed during selective serotonin reuptake inhibitor antidepressant treatment.  
 
In Study II, our results identified several cortical and subcortical regions, in 
addition to the amygdala, that showed automatic negative mood-congruent processing 
biases in unmedicated currently depressed individuals versus healthy controls. An 
increased hemodynamic response during exposure to masked-sad faces versus masked-
happy or masked-neutral faces was demonstrated in such regions as the hippocampus, 
inferotemporal cortex, superior temporal gyrus, orbitofrontal cortex, thalamus and 
pregenual anterior cingulate cortex, regions known to have substantial connections with 
the amygdala.  
 
In Study III, our results expanded on the antidepressant treatment findings from 
Study I and identified several regions of the medial and orbital prefrontal cortical 
networks associated with the amygdala that showed differential processing of negative 
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emotional information under antidepressant treatment. Most notably, the pregenual 
anterior cingulate response to masked-sad versus masked-happy faces decreased 
following antidepressant treatment. Similar to our amygdala findings, a shift in the 
pattern of results was observed such that the hemodynamic response decreased to 
masked-sad faces while the hemodynamic response increased to masked-happy faces.  
 
These studies showed for the first time in unmedicated individuals with dMDD 
that mood-congruent processing biases present in the amygdala toward emotional 
stimuli presented below the level of conscious awareness involve a resolution of the 
negative emotional processing bias and the development of a normative positive 
processing bias under antidepressant treatment. 
 
Taken together, the presence of non-conscious mood-congruent processing 
biases in the amygdala and network of regions associated with amygdala may function 
to influence the salience of social stimuli and contribute to the maintenance of 
dysfunction in social perceptions and interactions associated with major depressive 
disorder. These studies provide important information regarding the underlying 
neurocircuitry associated with automatic processing biases and implicate several 
regions influenced by antidepressant treatment. This knowledge of the neural processes 
associated with the emotional dysregulation in major depressive disorder may hold the 
potential to direct future therapeutic approaches for the treatment of mood disorders 
with abnormalities in emotional processing. 
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6 FUTURE PERSPECTIVES 
 
6.1  FUTURE DIRECTIONS 
 
Additional studies are needed to explore the neural mechanisms that function to 
produce changes in the processing of emotional stimuli and to assess whether these 
changes may provide a sensitive and specific biomarker of antidepressant treatment 
response and vulnerability to relapse. Developmental studies are needed to determine if 
the processing biases extant in MDD may represent a potential endophenotype and to 
explore the relationship of this finding with the emergence, maintenance and recurrence 
of major depressive episodes throughout the lifespan. These studies would also assist in 
establishing whether the present findings are mood-state dependent or instead reflect 
trait-like biases that precede or persist across mood episodes. Furthermore, additional 
studies are needed to address limitations of the current studies by expanding the 
paradigm to include other mood disorders, such as bipolar disorder, or to anxiety 
disorders that often occur co-morbidly with depression, such as social anxiety disorder, 
as well as to assess the effects of other antidepressant drug classes (e.g. dual-reuptake 
inhibitors). The relatively small number of participants included in the treatment 
portion of the study may also be expanded, allowing for explorations into possible 
gender differences in emotional processing biases and an evaluation of the processing 
biases shown in individuals who do and do not respond to antidepressant treatment. 
 
6.2 BACKWARD MASKING TASK DESIGN MODIFICATION 
 
The original version of the backward masking task included a slow event-
related design in order to allow the hemodynamic response to return to baseline and 
reduce overlap of the neural response between conditions. While the design showed 
robust responses to emotional stimuli, it did not include an explicitly modeled baseline 
measure. The backward masking task has recently been modified and updated to a 
rapid event-related design to allow for improved modeling of an explicit baseline 
measure. The new design also permits more trials to be completed in a single session 
and less time in the scanner, thereby reducing the likelihood of motion artifact. The 
new design has been piloted and extended with promising findings at the Laureate 
Institute for Brain Research on a state of the art GE Discovery MR750 scanner and coil 
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system that allows for twice the signal-to-noise ratio of the scanner used to acquire the 
original results. 
 
6.3 INTERNAL FUNDING SUPPORT 
 
The following ongoing study protocols have been funded by the Warren Foundation at 
the Laureate Institute for Brain Research involving extensions of the thesis work using 
the backward masking task paradigm (Principal Investigator: Wayne Drevets, M.D., 
Co-Investigators: Teresa Victor, Jonathan Savitz, Ph.D., Julie Frost-Bellgowan, M.S.): 
 
1. Functional neuroanatomical networks underlying emotional processing biases 
to affective stimuli in mood and anxiety disorders  
 
The aims of this research are to 1) investigate the pathophysiology of mood and 
anxiety disorders including major depressive disorder, bipolar disorder and social 
anxiety disorder, 2) establish the neural networks involved in emotional information 
processing to conscious and non-conscious stimuli, 3) determine specific 
endophenotypes related to emotional processing in individuals at risk for developing 
major depressive disorder, 4) determine the effect of genetics, immune system and 
endocrine system dysfunction on emotional processing of facial stimuli, 5) differentiate 
trait-like versus mood-state dependent neural response abnormalities, and 6) identify 
effective antidepressant treatments directed at neuroanatomical regions involved in 
mood and anxiety disorders 
 
2. Neurophysiological correlates of emotion processing in mood disorders 
during development and aging  
 
The purpose of this study is to investigate the functional neuroanatomical 
networks underlying emotional processing biases across the lifespan beginning in 
childhood in individuals with a primary mood disorder (major depressive disorder or 
bipolar disorder), healthy controls and high risk controls with a first-degree relative 
with a mood disorder or personal history of a childhood anxiety disorder. The study 
aims to: 1) establish the neural networks involved in emotional information processing 
and 2) determine specific endophenotypes of mood disorders by assessing differences 
among “at risk” individuals who do, and do not, develop mood disorders. These studies 
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may help to inform new methods for early detection, intervention and possibly 
prevention of mood disorders. 
 
6.4 EXTERNAL FUNDING SUPPORT 
 
The work performed for this thesis has resulted (in whole or in part) in several 
successful grant applications awarded to investigators at the Laureate Institute for Brain 
Research. Each of these grants includes the backward masking task paradigm as the 
functional neuroimaging component of the study: 
 
1. Oklahoma Center for the Advancement of Science and Technology (OCAST) 
Oklahoma Health Research Program: Principal Investigator- Wayne Drevets, 
M.D., Lead Investigator- Teresa Victor. The goal of this grant proposal is to 
extend the findings obtained in this thesis work and establish whether the 
neurophysiological correlates of the emotional processing biases may provide a 
biomarker to sensitively and specifically predict the response to antidepressant 
treatment using SSRIs in MDD. The results hold the potential to identify 
individuals who will be more likely to improve and respond to SSRIs prior to 
treatment and facilitate the development of more effective antidepressant 
pharmacotherapies by improving the power of clinical trials. 
 
2. Brain and Behavior Research Foundation (formerly NARSAD, the National 
Alliance for Research on Schizophrenia and Depression): Principal 
Investigator- Jonathan Savitz, Ph.D. The goal of this grant was to evaluate 
whether the negative emotional processing bias shown in these studies using the 
backward masking paradigm is an illness-dependent trait or endophenotype that 
predisposes individuals to develop major depressive disorder. A “high-risk” 
group of healthy individuals with first-degree relatives with MDD was 
compared to a currently depressed MDD group and a group of healthy controls 
with no first-degree relatives with psychiatric illness. 
 
3. National Institute of Mental Health RO1: Dimensional Approaches to Research 
Classification in Psychiatric Disorders Award. Principal Investigator- Wayne 
Drevets, M.D., Co-Investigator- Teresa Victor. The goal of this grant is to 
elucidate the relationship between anhedonia, inflammation, gene expression 
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and the function of positive valence systems to establish a pathophysiology-
based phenotype within mood disorders. In addition, the grant seeks to develop 
a biomarker signature composed of multiple measures that sensitively and 
specifically classify individuals with mood disorders and predicts treatment 
outcomes.  
 
4. National Institute of Mental Health Parent K01: Mentored Research Scientist 
Development Award. Principal Investigator- Jonathan Savitz, Ph.D. The goal of 
this grant is to identify the biological pathways through which inflammation 
affects brain structure and function in major depressive disorder and through the 
knowledge of these molecular targets guide the development of next-generation 
antidepressant medications. 
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